172 related articles for article (PubMed ID: 27487788)
1. Identification of Novel Structurally Diverse Anaplastic Lymphoma Kinase Inhibitors Based on Pharmacophore Modeling, Virtual Screening and Molecular Docking.
You R; Zhou L; Zhong L; Li X; Zhou S; Tian Y
Comb Chem High Throughput Screen; 2016; 19(9):691-704. PubMed ID: 27487788
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.
James N; Ramanathan K
Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056
[TBL] [Abstract][Full Text] [Related]
3. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.
Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY
Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.
Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW
J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102
[TBL] [Abstract][Full Text] [Related]
9. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel NAMPT inhibitors based on pharmacophore modeling and virtual screening techniques.
Yi Q; Zhou L; Shao X; Wang T; Bao G; Shi H; Zhou S; Li X; Tian Y
Comb Chem High Throughput Screen; 2014; 17(10):868-78. PubMed ID: 25413783
[TBL] [Abstract][Full Text] [Related]
12. 3D QSAR pharmacophore-based virtual screening for the identification of potential inhibitors of tyrosinase.
Ghayas S; Ali Masood M; Parveen R; Aquib M; Farooq MA; Banerjee P; Sambhare S; Bavi R
J Biomol Struct Dyn; 2020 Jul; 38(10):2916-2927. PubMed ID: 31334690
[TBL] [Abstract][Full Text] [Related]
13. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors.
Sakkiah S; Thangapandian S; John S; Lee KW
Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2.
Sakkiah S; Thangapandian S; Lee KW
J Mol Model; 2012 Jul; 18(7):3267-82. PubMed ID: 22249747
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
17. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Pathak D; Chadha N; Silakari O
J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
[TBL] [Abstract][Full Text] [Related]
18. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
Kaur M; Silakari O
SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
[TBL] [Abstract][Full Text] [Related]
19. Scaffold hopping for identification of novel PKCβII inhibitors based on ligand and structural approaches, virtual screening and molecular dynamics study.
Grewal BK; Sobhia ME
Comb Chem High Throughput Screen; 2014 Jan; 17(1):2-11. PubMed ID: 24050690
[TBL] [Abstract][Full Text] [Related]
20. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
